241 related articles for article (PubMed ID: 25792472)
1. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.
Kilic L; Yildiz I; Sen FK; Erdem MG; Serilmez M; Keskin S; Ciftci R; Karabulut S; Ordu C; Duranyildiz D; Tas F
Cancer Biomark; 2015; 15(4):405-11. PubMed ID: 25792472
[TBL] [Abstract][Full Text] [Related]
2. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
[TBL] [Abstract][Full Text] [Related]
3. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
Blackwell K; Hurwitz H; Liebérman G; Novotny W; Snyder S; Dewhirst M; Greenberg C
Cancer; 2004 Jul; 101(1):77-82. PubMed ID: 15221991
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
7. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
8. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer.
Stiksma J; Grootendorst DC; van der Linden PW
Clin Colorectal Cancer; 2014 Dec; 13(4):239-44. PubMed ID: 25442815
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
[TBL] [Abstract][Full Text] [Related]
10. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
11. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
12. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of D-dimer in lung cancer.
İnal T; Anar C; Polat G; Ünsal İ; Halilçolar H
Clin Respir J; 2015 Jul; 9(3):305-13. PubMed ID: 24720709
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.
Wang RF; Song BR; Peng JJ; Cai GX; Liu FQ; Wang MH; Cai SJ; Ye X
Hepatogastroenterology; 2014 Jun; 61(132):994-9. PubMed ID: 26158155
[TBL] [Abstract][Full Text] [Related]
16. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
18. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
20. Preoperative carcinoembryonic antigen elevation in colorectal cancer.
Yeh CY; Hsieh PS; Chiang JM; Lai CC; Chen JS; Wang JY; Hung HY
Hepatogastroenterology; 2011; 58(109):1171-6. PubMed ID: 21937372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]